As cancer continues to be a major global health challenge, the role of TRIPS in shaping the landscape of cancer treatment is likely to evolve. Ongoing discussions and negotiations may focus on enhancing the balance between protecting patents and ensuring drug accessibility. The future of TRIPS in cancer treatment will depend on how effectively it can adapt to the needs of both global health and the pharmaceutical industry's innovation goals.
